Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763429 | 0.95 | FFAR1 (0.42) | FFAR1CTSLAURKARPS6KB1GAA | |
| SCHEMBL6706968 | 0.94 | FFAR1 (0.41) | FFAR1CTSLAURKARPS6KB1GAA | |
| SCHEMBL6708995 | 0.93 | FFAR1 (0.41) | FFAR1CTSLAURKARPS6KB1GAA | |
| SCHEMBL6707009 | 0.91 | PDE11A (0.43) | PDE5A | |
| SCHEMBL6709004 | 0.90 | PDE5A (0.43) | PDE5A | |
| SCHEMBL6710422 | 0.88 | P2RX3 (0.46) | — | |
| SCHEMBL6710419 | 0.87 | PDE5A (0.43) | FFAR1PDE5A | |
| SCHEMBL6712268 | 0.86 | PDE11A (0.43) | PDE5A | |
| SCHEMBL6707605 | 0.86 | CHRM4 (0.42) | AURKARPS6KB1GAAPDE5A | |
| SCHEMBL6708873 | 0.86 | PDE11A (0.42) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777419-B1 | EXHIBIT PHOSPHODIESTERASE V INHIBITION AND CAN BE EMPLOYED FOR THE TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM OR ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1357904-A2 | USE OF PYRAZOLO 4,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1355649-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GmbH (DE) | 2003-10-29 | — | — | EP | disclosed |
| EP-1343506-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1339410-A1 | USE OF PYRAZOLO 4,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1210349-B1 | PYRAZOLO 4,3-d]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002060449-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GMBH (DE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002045716-A1 | USE OF PYRAZOLO[4,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-1210349-A2 | PYRAZOLO 4,3-d]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002041880-A2 | USE OF PYRAZOLO[4,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001018004-A2 | PYRAZOLO[4,3-d]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | FFAR1 3222/4885CTSL 2296/4885AURKA 1662/4885 |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | P2RX3, HRH2, HRH4 | FFAR1 1550/4885CTSL 2427/4885AURKA 1548/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | FFAR1 1125/4885CTSL 1887/4885AURKA 1411/4885 |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | DPYD, TYMP, PNPO | FFAR1 4131/4885CTSL 2454/4885AURKA 411/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | FFAR1 602/4885CTSL 1593/4885AURKA 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.